Ichiro Abe, “Efficacy and safety of low-dose ipragliflozin, a selective sodium glucose transporter 2 inhibitor, in patients with type 2 diabetes mellitus”, ijamscr, vol. 4, no. 3, pp. 376–382, Aug. 2020.